BVS 5000

BVS 5000

A proprietary cardiac assistance system approved by the FDA for patients with potentially reversible heart failure; the device was previously approved for patients who had been unable to be weaned from heart-lung devices after undergoing heart transplants.

BVS 5000 Components
(1) Pneumatic drive console that can operate one or two blood pumps independently, which can provide support to one or both ventricles without intensive bedside management.
(2) Cannulae, for blood drainage from and blood return to the patient, of varying designs that accommodate different patient anatomy, facilitating simple and efficient insertion.
References in periodicals archive ?
The Abiomed BVS 5000 product was the first ventricular assist device (VAD) ever approved by the FDA in 1991 based on an 83-patient PMA study.
The iPulse combination console drives Abiomed and other manufacturers intra-aortic balloons (IAB), Abiomed's BVS 5000 and AB5000 Ventricular Assist Devices (VAD), as well as new products Abiomed may offer in the future.
The BVS 5000 is able to provide left, right, or bi-ventricular support for any and all patients with reversible heart failure.
Based on the recent Centers for Medicare and Medicaid services (CMS) update on August 1, 2008, the BVS 5000 and AB5000 are the only ventricular assist devices (VADs) eligible for diagnostic related group 1 (DRG 1) for heart recovery.
The iPulse drives Abiomed and other manufacturers' intra-aortic balloons (IAB), Abiomed's BVS 5000 and AB5000 VADs, as well as new products Abiomed may offer in the future.
Abiomed's distributor for the AB5000 and BVS 5000 Circulatory Support Systems.
The Company also received CE Mark approval in Europe for both the Intra-Aortic Balloon and the new iPulse combination console system that can run Abiomed's IAB, BVS 5000 Blood Pump and AB5000 Ventricle.
Abiomed's new Intra-Aortic Balloon and iPulse(TM) combination console platform which is available in Europe and drives Abiomed's IAB, BVS 5000 and AB5000 Circulatory Support Systems.
The iPulse combination console platform drives Abiomed's IAB, BVS 5000 and AB5000 Circulatory Support Systems, as well as new product introductions planned by Abiomed in the future.
Abiomed now has a full spectrum of patient support technologies including our new Intra-Aortic Balloon, breakthrough Impella technologies, BVS 5000 and AB5000 Circulatory Support Systems and the AbioCor, recently approved by the FDA after 25 years of development.
Published results have demonstrated that heart recovery is the most likely outcome for acute heart failure patients when supported with the Abiomed AB5000 and BVS 5000 systems while following established protocols.
Raess has consulted for the company over the years beginning with the initial clinical trials for the BVS 5000 in 1989, which was published in the peer-reviewed journal the Annals of Thoracic Surgery.